Adial Pharmaceuticals (ADIL) Capital Expenditures (2021)

Adial Pharmaceuticals (ADIL) posted Capital Expenditures of $33730.0 for Q2 2021, up 9.25% sequentially from $30875.0 in Q1 2021.

Adial Pharmaceuticals (ADIL) Capital Expenditures (2021) Analysis & Trends

Adial Pharmaceuticals has reported Capital Expenditures for 1 years, with the latest figure at $33730.0 in Q2 2021.

Quarterly Capital Expenditures changed N/A year-over-year to $33730.0 in Q2 2021, while the trailing twelve-month figure through Dec 2021 was $64605.0 (changed N/A YoY) and the FY2021 annual result came in at $64605.0, changed N/A from the prior year.
Capital Expenditures rose to $33730.0 in Q2 2021 per ADIL's latest filing, from $30875.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $33730.0 in Q2 2021 and troughed at $30875.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.69 Bn	78.70 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.23 Bn	60.05 Bn	1.37 Bn	-
4	Moderna	60.16 Bn	55.02 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.86 Bn	28.55 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.24 Bn	9.85 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	251.02 Mn
10	Adial Pharmaceuticals	27.27 Mn	27.27 Mn	-	-

Download Data